Lamisil Oral: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing

Uses

Terbinafine is used to treat certain types of fungal infections (for example, of the fingernail or toenail). It works by stopping the growth of fungus. This medication belongs to a class of drugs known as antifungals.

How to use Lamisil 250 Mg Tablet

Read the Medication Guide provided by your pharmacist before you start taking terbinafine and each time you get a refill. If you have any questions, ask your doctor or pharmacist.

Take this medication by mouth with or without food, usually once a day or as directed by your doctor. Dosage and length of treatment is based on your medical condition and response to treatment.

It may take several months after you finish treatment to see the full benefit of this drug. It takes time for your new healthy nails to grow out and replace the infected nails.

Continue to take this medication until the full prescribed amount is finished. Stopping the medication too early may allow the fungus to continue to grow, which may result in a return of the infection.

Tell your doctor if your condition lasts or gets worse.

Side Effects

Diarrhea or stomach upset may occur. If either of these effects lasts or gets worse, tell your doctor or pharmacist promptly.

Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Changes in your sense of taste/smell or loss of taste/smell may occur. These side effects may improve after stopping terbinafine, but can last for a long time or become permanent. Tell your doctor right away if you notice either of these side effects.

Tell your doctor right away if you have any serious side effects, including: vision changes, mental/mood changes (such as depression), unexplained bleeding/bruising, unusual tiredness, signs of kidney problems (such as change in the amount of urine).

Terbinafine may rarely cause serious (possibly fatal) liver disease. Get medical help right away if you have any symptoms of liver damage, such as: nausea/vomiting that doesn’t stop, loss of appetite, severe stomach/abdominal pain, yellowing eyes/skin, dark urine.

A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: fever, swollen lymph nodes, rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US – Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.

In Canada – Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

Precautions

Before taking terbinafine, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: immune system problems, kidney disease, liver disease, lupus.

Limit alcoholic beverages. Daily use of alcohol may increase your chance for serious side effects.

This medication may make you more sensitive to the sun. Limit your time in the sun. Avoid tanning booths and sunlamps. Use sunscreen and wear protective clothing when outdoors. Tell your doctor right away if you get sunburned or have skin blisters/redness.

During pregnancy, this medication should be used only when clearly needed. Fungal nail infection treatment can usually wait until after you have had your baby. Discuss the risks and benefits with your doctor.

This drug passes into breast milk. Consult your doctor before breast-feeding.

Interactions

Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor’s approval.

Terbinafine can slow down the removal of other drugs from your body, which may affect how they work. Examples of affected drugs include pimozide, thioridazine, among others.

Does Lamisil 250 Mg Tablet interact with other drugs you are taking?

Enter your medication into the WebMD interaction checker

Overdose

If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.

Do not share this medication with others.

This medication has been prescribed for your current condition only. Do not use it later for another infection unless your doctor tells you to.

Lab and/or medical tests (such as complete blood counts, liver function tests) should be done before you start taking this medication and while you are taking it. Keep all medical and lab appointments. Consult your doctor for more details.

If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.

Store at room temperature away from light and moisture. Do not store in the bathroom. Keep all medications away from children and pets.

Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.

How and when to take or use terbinafine

The treatment you use will depend on where the infection is on your body and how severe it is.

For large areas of skin, or if the area is hairy, it’s best to use the spray.

If you buy terbinafine in a pharmacy or shop, follow the instructions that come with your medicine.

Dosage

Your doctor or pharmacist will tell you how much terbinafine to use and how long you need to use it for, depending on your infection.

If you’re using the cream, gel or spray, you’ll usually need to use it once or twice a day.

If you’re using the solution, you only use it once.

If you’re taking the tablets, the usual dose is 1 tablet, taken once a day. You’ll usually take the tablets for 2 to 6 weeks. This depends on the type of infection you have and how serious it is.

How to use terbinafine cream or gel

Put the cream or gel on the infected area once or twice a day for 1 to 2 weeks.

1. Wash your hands before using the cream or gel.
2. Wash and dry the infected skin where the cream or gel will go. If you’re treating your feet, it’s also important to wash and dry between your toes first.
3. Unscrew the cap.
4. Squeeze out a small amount of the cream or gel onto your finger (enough to put a thin layer on your skin).
5. Gently rub it into the infected areas. Avoid putting it near your mouth, lips and eyes.
6. Replace the cap.
7. Wash your hands.

If you’re using the cream or gel on the area between your toes, or on your bottom or groin, you can cover the skin with a clean strip of gauze afterwards. This type of light dressing is available to buy at pharmacies and is especially helpful to use at night.

How to use terbinafine spray

Put the spray on the infected area once or twice a day for 1 to 2 weeks.

1. Wash your hands before using the spray.
2. Wash and dry the infected skin before using the spray. If you’re treating your feet, it’s also important to wash and dry between your toes first.
3. Take the cap off and prepare the spray by pressing the top of the spray down once or twice.
4. Hold the bottle about 10cm away from the infected area and spray until your skin is thoroughly wet. Avoid getting it near your mouth, lips and eyes.
5. Replace the cap.
6. Wash your hands.

If you’re using the spray on the area between your toes, or on your bottom or groin, you can cover the skin with a clean strip of gauze afterwards. This type of light dressing is available to buy at pharmacies and is especially helpful to use at night.

How to use terbinafine solution (Lamisil Once)

The solution for athlete’s foot comes in a tube with a nozzle. It’s a single treatment that you only use once.

Use the solution on both feet even if one of them looks fine. If one foot looks less infected than the other, put the solution on the less infected foot first.

1. Use the solution after a shower or bath. Before using the solution, make sure your feet are dry, including between your toes.
2. Remove the cap.
3. Put the solution all over your toes, including between each toe, and on the sole, top and sides of your foot. This should use about half the tube. Finish treating this foot before treating the other.
4. Do not rub or massage the solution in.
5. Leave the solution to dry on your feet for 1 to 2 minutes.
6. Replace the cap and throw the tube away.
7. Wash your hands.
8. Put on your normal shoes and socks.

Do not wash or splash your feet with any water for 24 hours after using the solution.

After 24 hours, wash your feet with warm, soapy water in the bath or shower and gently pat them dry.

How to take terbinafine tablets

Swallow the tablet whole with a drink of water.

You can take terbinafine tablets with or without food. It’s best to take your tablets at the same time each day.

If you have a fungal nail infection, you’ll probably need to take the tablets for several months. These infections take a while to clear.

How long to take or use it for

If you’re using the cream, gel or spray, you’ll usually need to use it for 1 to 2 weeks. Talk to your doctor if your symptoms do not get better within 2 weeks.

If you’re taking the tablets, you’ll usually take them for:

• 2 to 4 weeks if you have jock itch
• 2 to 6 weeks if you have athlete’s foot
• 4 weeks if you have ringworm
• 6 weeks to 3 months (sometimes longer) if you have a fungal nail infection

It’s important to keep taking or using terbinafine until you finish the course, even if your symptoms get better. Follow the instructions from your doctor or on the leaflet that comes with the medicine.

If you stop using your terbinafine too soon, or if you do not use it as recommended, the fungal infection could come back.

Talk to your doctor if you’re thinking of stopping your treatment for any reason.

If you forget to take it or use it

If you forget to use your terbinafine cream, gel or spray, just use it as soon as you remember and then keep following your usual routine.

If you forget to take a terbinafine tablet, take it as soon as you remember, unless it’s nearly time for your next dose. In this case, just skip the missed dose and take your next one at the usual time. Then carry on until you have finished the course.

Do not take 2 doses to make up for a missed dose.

If you forget doses often, it may help to set an alarm to remind you. You could also ask your pharmacist for advice on other ways to help you remember your medicines.

If you take or use too much

If you use too much terbinafine cream, gel or spray or use it more often than you need to, it may make your skin irritated or red. If this happens, use less of the cream, gel or spray the next time.

Taking 1 or 2 extra terbinafine tablets is unlikely to harm you.

If you take more than this, you may get side effects including stomach pain, feeling or being sick, diarrhoea, headache or feeling dizzy.

Urgent advice: Contact 111 for advice now if:

• you take a lot of terbinafine tablets at the same time (4 or more) even if you have no side effects
• you take 2 or more terbinafine tablets and have side effects

Call 111 or go to 111. nhs.uk. Call 111 if you need advice for a child under the age of 5 years.

If you need to go to A&E do not drive yourself. Get someone else to drive you or call for an ambulance.

Take the terbinafine packet, or the leaflet that came with your medicine, and any remaining medicine with you.

Lamisil in the treatment of onychomycosis | Volkova E.N.

O nichomycosis is one of the most common human diseases. Fungal nail disease is currently thought to occur in 50% of patients with nail plate lesions. In Russia, the number of patients with onychomycosis varies from 4.5 to 15 million people.

The causative agents of onychomycosis are dermatophytes, yeasts, molds, however, their ratio in the incidence spectrum is estimated by researchers in different ways. The vast majority (91.3%) of patients identified dermatophytes – primarily Tr. rubrum (72%), rarely Tr. menthagrophytes (19.3%) [1, 15, 21] (Fig. 1.). In particular, Tr. rubrum , as a rule, is the cause of damage to the nail plates of the feet; yeast usually infects the nails on the hands, and non-dermatophytic molds, which cause 3–5% of onychomycosis, on the feet [23]. Mostly yeasts and molds are found in combination with Tr. rubrum .

Fig. 1. Proportion of pathogens in the etiology of onychomycosis

Predisposing factors for the development of mycotic infection include diseases of the vessels of the lower extremities (obliterating endarteritis, thrombophlebitis, varicose veins, Raynaud’s syndrome), systematic microtrauma of the nail plate, and dystrophic conditions. Usually, these factors make it difficult to treat onychomycosis, especially if the patient has a combined pathology of the nail (for example, mycosis on the background of psoriasis).

In the pathogenesis of onychomycosis, an essential role belongs to the pathology of carbohydrate metabolism, endocrine and neurological changes, disorders of the immune system. The disease often develops against the background of long-term use of drugs that suppress the body’s defenses (glucocorticoids, cytostatics, broad-spectrum antibiotics). According to the literature [8, 23], onychomycosis is registered in 40% of cases in people over 65 years of age with age-related immunosuppression.

The vast majority of cases of onychomycosis is characterized by a chronic persistent course. It is believed that with the defeat of Tr. rubrum , this is due to the impossibility of developing a specific immune response against the fungus due to the activity of special T-suppressor cells. The suppression of the cellular and the absence of an inflammatory response to the pathogen may also be due to its predominant localization in the stratum corneum of the epidermis and nail plates.

The literature provides numerous data on the comparative effectiveness of various methods of onychomycosis therapy: local application of antimycotics in the form of ointments, patches, varnishes, surgical removal of the nail plate, followed by treatment of the nail bed with antifungal drugs, as well as systemic antimycotics [1, 2, 12, 28 ]. An analysis of publications on the problem indicates that in world medical practice there is still no ideal remedy and method for the treatment of onychomycosis, which would be suitable for all patients without exception, would not give any side effects and in a short time provide 100% clinical and etiological cure of the patient. Therefore, even today the search and comprehensive study of new effective antimycotics that meet these requirements is justified.

Terbinafine (Lamisil, created in 1982 by the Swiss company Novartis) is a representative of the class of allylamines – chemical compounds included in the arsenal of the most effective means of treating dermatomycosis.

To date, after multilateral clinical trials, Lamisil has firmly entered the practice of treating patients with mycoses [11, 22, 29, 31]

This drug with a wide spectrum of antifungal activity [16, 34]. In therapeutic concentrations, it has a direct fungicidal effect on dermatophytes, yeasts and molds, both when administered orally and topically. The site of application of the drug is the cytoplasmic membrane of the fungal cell. The advantage of terbinafine is its action at the early stages of sterol metabolism, at the level of the squalene epoxidase cycle. By inhibiting the enzyme squalene epoxidase, terbinafine inhibits the formation of ergosterol, the main component of the cell wall of fungi, preventing their further reproduction [15, 19, 22].

The drug has a dual mechanism of action: fungicidal and fungistatic, and the fungicidal effect is the main one. It is caused by the accumulation of squalenes in the fungal cell, which, like a kind of lipid sponge, extract lipid components from the membranes. The lipid granules accumulating inside the cell, gradually increasing in volume, break the defective cytoplasmic membranes, leading the fungal cell to death [11, 17]. The fungistatic effect is due to the defectiveness of the membranes of the fungal cell due to the suppression of the synthesis of ergosterol, which leads to the loss of the ability of the fungal cell to develop – it only survives.

The predominant fungicidal effect of lamizil, which distinguishes it from previously created systemic antimycotics, determines the higher efficacy of the drug, as well as a smaller number of relapses in its use, due to which treatment is cheaper than other systemic antimycotics [9, 14].

The drug is well absorbed from the gastrointestinal tract: 2 hours after a single dose of 250 mg, its plasma concentration is 0.8-1.5 mg/ml. Due to its lipophilicity, it accumulates in the dermis, epidermis, adipose tissue, from where it is slowly absorbed into the blood [19].]. Terbinafine also penetrates the secretion of the sebaceous glands, which leads to the creation of the highest possible concentrations in the hair follicles, hair and skin rich in sebaceous glands. The drug is found in the stratum corneum of the epidermis within a few hours after oral administration, which is achieved by its excretion by the sebaceous glands and, to a lesser extent, by passive diffusion [11, 17]. Terbinafine is characterized by long-term persistence in the blood due to the continuous regimen of the drug, which is an important component of its pronounced effectiveness. In the distal parts of the nails, its concentration persists for 48 weeks after the end of the course of therapy, which causes a positive fungicidal effect and makes it possible to cure onychomycosis without removing the nail plates [19, 29]. Biotransformation leads to the formation of metabolites that do not have antimycotic activity, which are excreted from the body mainly with urine [9].

Distribution features of terbinafine include its lymphatic transport due to its lipophilicity and association with chylomicrons. Through the lymphatic vessels, terbinafine directly reaches infiltrative-suppurative and abscessed lesions complicated by lymphangitis. This nature of terbinafine transport, combined with its antibacterial properties comparable to those of gentamicin, leads to a fairly rapid resolution of complicated forms of dermatophytosis [23].

The drug does not suppress liver enzymes, binding little to cytochrome p-450, as a result of which it practically does not affect the metabolism of drugs, i.e. the risk of drug interactions is minimal. This is an important advantage of the drug, since it ensures safety in the treatment of patients receiving concomitant therapy for intercurrent diseases (diabetes mellitus, diseases of the cardiovascular, nervous systems, etc.) [21, 31]. The bioavailability of terbinafine as a result of co-administration with other drugs and food does not change. At a concentration 5 times higher than therapeutic, terbinafine does not inhibit chemotaxis, phagocytosis and metabolic activity of leukocytes, i.e. does not have an immunosuppressive effect [34]. Moreover, Barbareschi, 1993 [13] showed that in vitro incubation of polymorphonuclear neutrophils with terbinafine leads to an increase in their activity [13].

Lamisil has an excellent safety profile [20, 36, 39, 40]. Its safety is comparable to placebo [29]. According to the data presented by a number of authors [16,27], according to the results of the analysis of case histories of 25884 patients who took pills, the side effects that occurred when taking lamisil are extremely rare and refer mainly to mild gastrointestinal events (Table 1). ).

All the noted properties of the drug contributed to its rapid introduction into clinical practice in more than 80 countries around the world [17, 21, 25, 27]. The data of foreign researchers given in the table testify to the high efficiency of lamisil in the treatment of onychomycosis. The positive experience of treatment with lamisil is also noted by many domestic scientists, demonstrating very impressive performance.

Thus, according to A.A. Kubanova [4], a positive clinical effect and microbiological cure were observed in 94.4% of patients. The results of Yu.V. Sergeev [9], which demonstrates clinical and mycological cure in 82% of patients. Data by N. S. Potekayeva [8] testify to the high efficiency of lamisil: mycological cure was obtained in 96% of patients (see Table 2). V.M. Leshchenko and G.M. Leshchenko [6] evaluate the results of treatment of patients with onychomycosis of the feet and hands, combined with lesions of smooth skin, as positive. At the end of the traditional course of treatment (250 mg once for 12 weeks), clinical recovery was noted in 96% of patients. The drug was well tolerated. In 478 patients after treatment with lamisil, fungi were not found microscopically in the material from the nail plates, and 6 months after the start of treatment, all of them had a clinical and microbiological cure.

According to V.A. Molochkova [5], in the treatment of patients with onychomycosis, the use of lamisil turned out to be highly effective, a positive clinical effect and microbiological cure were noted in 9 patients.5.2% of patients. Interesting data on the use of lamisil in patients with diabetes were obtained by S. A. Burovaya [3]. The presented long-term results (6 months after the end of treatment with lamisil) indicate that clinical recovery is observed in 85.7% of patients, microbiological sanitation in 89.3%. HE. Pozdnyakova demonstrates the efficacy and safety of lamisil in 48 patients with chronic liver diseases without exacerbation [8] in the compensated and subcompensated stages: after the end of therapy, mycological cure was observed in 100% of patients. Information about the use of lamisil in immunodeficiency states seems to be encouraging, given that the number of these patients is increasing every year. To date, 82 cases of the use of lamisil tablets in immunodeficiencies have been described: AIDS [26, 37, 38], Down’s syndrome, after organ transplantation [18, 24, 27].

Yu.K. Skripkin and Zh.V. Stepanova [10], summarizing the experience of domestic and foreign researchers, once again emphasized the effectiveness and safety of lamisil, good tolerance, and a convenient application regimen. The effectiveness of treatment, according to their data, was 94%.

Under our supervision there were 32 patients with onychomycosis of the feet (18 men, 14 women) aged 25 to 55 years with a disease duration of 1 to 15 years. Concomitant diseases were detected in 28% of patients, including gastritis, colitis, thyroid dysfunction; 50% of patients considered themselves practically healthy. Predisposing factors causing the development of the mycotic process were identified in 100% of patients. Thus, 26 patients were regular visitors to swimming pools, 18 to saunas; 14 patients were engaged in professional sports, which is associated with constant traumatization of the nail plates. The diagnosis of onychomycosis was established in each case on the basis of the clinical picture of the disease and the detection of fungi during microscopic examination of the affected nail plates. In 20 patients, in addition to onychomycosis (damage from 1 to 16 nail plates), there was a lesion of the skin of the corresponding localization: feet and hands (4 patients), smooth skin of the trunk (6 patients), large folds (10 patients). According to the clinical picture, the nail plates were affected mainly by a mixed type, i.e. in the same patient on different fingers they were changed according to the hypertrophic, normotrophic type with onycholysis phenomena and the area of ​​nail damage from marginal (5–10%) to total, involving the skin of the feet and palms in the process with skin changes characteristic of rubrophytosis exaggeration of skin furrows, small-lamellar (mucoid) peeling, hyperkeratosis, maceration of the epidermis, cracks in the interdigital folds of the skin of the feet.

Patients received Lamisil orally at 250 mg per day for 12 weeks, and during therapy, a complete blood count, urine, and liver function tests were examined. In each case, shoes were treated at home with a 25% formalin solution or a 0.5% solution of chlorhexidine bigluconate twice with an interval of 1 month. In order to increase the intensity of growth of the nail plate, 5 patients were prescribed phytin, zinc-containing vitamin complexes orally.

Patients tolerated the treatment well. Of the side effects in 1 patient, a temporary loss of taste sensations was noted: this phenomenon resolved itself without requiring drug withdrawal.

Control microscopic examination was performed 3, 4, 6 months after the start of treatment, and 6 months after the end of therapy, the results of microscopic examination were negative in 100% of cases. In 4 patients, despite the absence of fungi on microscopic examination, the nail plates remained dystrophically altered, and in each case they had a history of injury to the corresponding nail.

As a result of treatment, skin rashes, especially in large folds, resolved after 2-3 weeks. Affected nails with a lesion area of ​​up to 60% on the feet were replaced by visually healthy ones after 5–6 months, i.e. 3-4 months after the end of taking lamisil. There were no recurrences of the disease (9–14 months of follow-up).

Thus, on the basis of literature data and the results of our own research, it can be argued that the appearance of lamisil led to a significant improvement in the prognosis of patients suffering from onychomycosis, which was previously difficult to treat and was characterized by a persistent course. Lamisil therapy has changed the view that onychomycosis is difficult to cure: the drug is highly effective, provides a high cure rate in a shorter period than previous generations of antimycotics. The fungicidal effect, active penetration of lamisil into keratin and its long-term retention in the nail plate, combined with the relative rarity of serious adverse effects and relapses, made the drug the drug of choice in the treatment of fungal infections of the nails and smooth skin. It should be noted that at present it is included in the list of medicines for preferential services for the disabled and pensioners at the expense of the fund of insurance companies.

References can be found at http://www.rmj.ru

Terbinafine–

Lamisil (trade name)

(Novartis Pharma)

1. Afanasiev D.B. “Complex outpatient treatment of onychomycosis using biologically active dressings”, abstract of the dissertation of cand. med. Sciences, M., 1996, 23.

2. Bormotov V.Yu. “Outpatient treatment of patients with onychomycosis caused by red trichophyton”, Abstract of the dissertation of the candidate of medical sciences, M., 1983; 19.

3. Burova S.A., Talalaeva S.M., “Long-term results of the treatment of onychomycosis in patients with diabetes mellitus” “Russian Journal of Skin and Venereal Diseases”, 2000, No. 5, pp. 31–33.

4. Kubanova A.A., Sukolin G.I., Yusuf M., Yazdy M.Sh. “Bulletin of Dermatology and Venereology” 1995, No. 6, pp. 42-43 “The use of Lamisil in mycological practice”.

5. Kurcheva O.P., Molochkov V.A. “Lamisil is an effective remedy for the treatment of onychomycosis” “Russian Journal of Skin and Venereal Diseases” 1998, No. 1, 47–49.

6. Leshchenko V.M., Leshchenko G.M. “Treatment of onchomycosis with Lamisil” “Bulletin of Dermatology and Venereology”, 1998, No. 2, pp. 61–64.

7. Lykova S. G., Pozdnyakova O. P. “Bulletin of dermatology and venereology”, 2000, No. 4

8. Potekaev N. S. “Bulletin of dermatology and venereology”, 1999, No. 5

9. Sergeev Yu.V., Potekaev N.S., Leshchenko V.M., Larionova V.N. “Bulletin of Dermatology and Venereology” 1995 No. 5 pp. 54–56 “Lamisil: improving the treatment of onychomycosis caused by dermatophytes.”

10. Skripkin Yu.K., Stepanova Zh.V. “Bulletin of Dermatology and Venereology” No. 6, 1999. 11 11. Alpsoy E., Yilmanz E., Basaran E. Intermettent therapy with terbinafine for dermatophyte toe onychomycosis a new approach.– J. Dermatol, 1996, 23:259–262

12. Back D.J., Tjia J.F., Abel S.M. Azoles, allylamines and drug metabolism. Br. J. Dermatol. 1992; 126 (Suppl. 33): 14–18.

13. Barbareschi M, Vago, Colombo D., Bevilacqua M. mycoses 36: 405–9 (1993), (LAS 360)

14. Clayton J.M. In vitro activity of terbinafine, Clin Ep. Dermatol. 1989; 14:101–103.

15. Clayton J.M., Hay K.J., Bnt. J. Dermatol. 1994 vol.130 suppl.43, p.9–11.

16. De Cnyper “Long-term outcome of onychomycosis treatments” Cl. Dermal, 1998; T.Z.

17. Einarson T.R., Lupta A.K., Shear N.H., Arikian S. Clinical and economic factors in the treatment of onychomy costs. Pharmacoeconomics 1996:307–320.

18. EnsenP. et al. ActaDermato-Venereologica76: 280-1 (1996)

19.Faergemann J., Lehender H., Milleriouv L. Levels of terbinafine in plasma, stratum comeum, dermis–epidermis (without stratum comeum), sebum, hair and nails during and after 250 mg terbinafme orally once daily for 7 and 14 days.–Clin. Exp. Dermatol. 19:121-6.

20. Hall M., Monka C., Krupp P., O’Sullivan Safety of oral terbinafme. Results of a Postmarketing Surveillance study in 25884 patients.–Archives of Dermal, 1997, v. 1213–1218.

21. Goodfield M.J.D., Br. J. Dermatol. 1992; 126 suppl. 33–35

22. Jones T.S. Overview of the use of terbinafme (Lamisil) in children. Br. J. of Dermatology; 1995; 132:683–689.

23. Lamisil (terbinafine hydrochloride tablets). Physicians’Desk Reference. 51st col Montvale, N. J.: Medical Economics; 1997,2334–95.

24. La Placa M et al. J. Dermatol. Tream 6:51–2(1995) (LAS 446)

25. Matsumoto T., Januma H., Kaneko S., Jakasu H., Nishiyama S. Clinical and pharmacokinetic investigations of oral terbinafme in patients with tinea unguium. – Mycoses 1995; 38:135–144.

26. Nandwani R. et al. Br J Dermatol. 134 (suppl. 46): 22–24 (1996) (LAS 563)

27 Norden J et al. Scand J Infect Lis 23: 377–82 (1991) (LAS 188) 2 8. Onychomy costs and terbinafine. Lancet 1990; 335:636

29. Polak A., Handbook of Experimental Pharmacology; Chemotherapy of Fungal Diseases 1990, p.96–153.

30. Roberts D.T. et al J. Amer. Assoc. Dermatol. 1994; 31 (suppl. 2) 578–581.

31. Roberts D.T. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey.– Br. J. Dermatol. 1992; 126 (Suppl. 39): 23–7

32. Roberts Dabriol. Abstracts of the 19th world congress of dermatology, 1997, Sydney, Australia

33. Rynder N. S. The mechanism of action of terbinafine. Clin. Exp. Dermatol. 1989; 14:98-100.

34. Shauder M. Mycoses 31: 259–67 (1988) (LAS 62)

35.Singer M.J. et al, J. Amer. Acad Dermatol. 1997, 37; 765–771.

36. Suhonen R. and Neuvonen P., Rev.Contemp.Pharmacother, 1997; 8; 373–386.

37. Villars V et al. Br J Dermatol 126 (suppl 39): 61–9 (1992) (LAS 208)

38. Velthuis PJ et al. Br J Dermatol 144-6 (1995) (LAS 465).

39. Williams and Hall M. “A review of the Safety of oral terbinafine (Lamisil) when used with oral coutraceptives and in pregnancy in a Postmarketing Surveillance Study.”– Book of abstracts, poster No. 81, Sing., 1988, 12 –20.06, p.l 18.

40. Williams T, Lanslandt J. and Jones T. A review of the efficacy and tolerability of terbinafine in children. Poster presented at 8th International Congress Pediatric Dermatology, 1998.

instructions for use, price, analogues, composition, indications

Hypersensitivity to terbinafine or to any of the inactive ingredients that make up the drug.

Method Applications and doses

Outwardly. Adults and children over the age of 12.

Before applying the cream, clean and dry the affected areas. The cream is applied once or twice a day with a thin layer on the affected skin and adjacent areas and lightly rubbed. For infections accompanied by diaper rash (under the mammary glands, in the interdigital spaces, between the buttocks, in the inguinal region), the places where the cream is applied can be covered with gauze, especially at night.

Average duration of treatment

A decrease in the severity of clinical manifestations is usually noted in the first days of treatment. In case of irregular treatment or its premature termination, there is a risk of recurrence of the infection. If after one to two weeks of treatment there are no signs of improvement, you should consult a doctor.

Dosing regimen of Lamisil cream in the elderly

Does not differ from the above.

Pediatric use

Experience with Lamisil cream in children under 12 years of age is limited. In this regard, the use of this drug in children under 12 years of age is not recommended.

Use during pregnancy and lactation

In experimental studies, the teratogenic properties of terbinafine have not been identified. To date, no malformations have been reported with the use of Lamisil. However, since the clinical experience with Lamisil in pregnant women is very limited, it should only be used under strict indications.

Terbinafine is excreted in breast milk. Do not use Lamisil Cream while breastfeeding.

Side effects

Redness, itching or burning sensation, peeling of the skin, pain or irritation may appear at the sites of application of the drug, but discontinuation of treatment due to these phenomena is rarely required. These less serious side effects should be distinguished from rare allergic reactions (eg, generalized rash and / or redness, urticaria, angioedema, repeated allergic reaction), the development of which requires discontinuation of treatment. In rare cases, an exacerbation of a fungal infection is possible.

In the event of an adverse event, even if it is not mentioned above, you should inform your doctor.

Overdose

No cases of drug overdose have been reported. If Lamisil cream is accidentally taken orally, the same side effects can be expected as with an overdose of Lamisil tablets (headache, nausea, epigastric pain and dizziness).

Treatment: activated charcoal, if necessary – symptomatic supportive therapy.